| 1.35 -0.04 (-2.88%) | 09-18 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.65  |
1-year : | 1.89 |
| Resists | First : | 1.41 |
Second : | 1.62 |
| Pivot price | 1.29 |
|||
| Supports | First : | 1.09 |
Second : | 0.9 |
| MAs | MA(5) : | 1.27 |
MA(20) : | 1.34 |
| MA(100) : | 1.87 |
MA(250) : | 1.94 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 50.6 |
D(3) : | 37.5 |
| RSI | RSI(14): 49.7 |
|||
| 52-week | High : | 3.25 | Low : | 1.09 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ LYEL ] has closed below upper band by 38.0%. Bollinger Bands are 22.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.43 - 1.44 | 1.44 - 1.44 |
| Low: | 1.29 - 1.3 | 1.3 - 1.31 |
| Close: | 1.34 - 1.35 | 1.35 - 1.36 |
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Mon, 09 Sep 2024
Lyell Immunopharma stock hits 52-week low at $1.14 - Investing.com
Mon, 02 Sep 2024
Lyell Immunopharma, Inc. (NASDAQ:LYEL) Short Interest Update - MarketBeat
Wed, 28 Aug 2024
Lyell Immunopharma Announces Participation in September Investor Conferences - GlobeNewswire
Wed, 07 Aug 2024
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2024 - GlobeNewswire
Mon, 01 Jul 2024
Lyell Immunopharma Drops To US$1.45, Yet Insiders May Have Sold Too Early - Simply Wall St
Wed, 26 Jun 2024
Lyell Immunopharma’s Promising CAR T-Cell Therapy Trial Results - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 256 (M) |
| Held by Insiders | 1.6529e+008 (%) |
| Held by Institutions | 15.3 (%) |
| Shares Short | 16,320 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.0447e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -396 % |
| Return on Assets (ttm) | 369.2 % |
| Return on Equity (ttm) | -18.9 % |
| Qtrly Rev. Growth | 54000 % |
| Gross Profit (p.s.) | 0.33 |
| Sales Per Share | 0.19 |
| EBITDA (p.s.) | -0.76 |
| Qtrly Earnings Growth | -0.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -158 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0.1 |
| Price to Book value | 0 |
| Price to Sales | 6.99 |
| Price to Cash Flow | -0.33 |
| Dividend | 0 |
| Forward Dividend | 1.376e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|